TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential
Mansour Poorebrahim, Niloufar Mohammadkhani, Reza Mahmoudi, Monireh Gholizadeh, Elham Fakhr, Ángel Cid-Arregui
Abstract
Neoepitopes or neoantigens are a spectrum of unique mutations presented in a particular patient's tumor. Neoepitope-based adoptive therapies have the potential of tumor eradication without undue damaging effect on normal tissues. In this context, methods based on the T cell receptor (TCR) engineering or chimeric antigen receptors (CARs) have shown great promise. This review focuses on the TCR-like CARs and TCR-CARs directed against tumor-derived epitopes, with a concerted view on neoepitopes. We also address the current limitations of the field to know how to harness the full benefits of this approach and thereby design a sustained and specific antitumor therapy.